Central Pontine Myelinolysis Market to Experience Exponential Growth by 2023

Market Highlights:

The market drivers for central pontine myelinolysis market are increasing risk factors and cases of liver disease, liver transplant, alcoholism, severe burns, malnutrition, anorexia, severe electrolyte disorders, AIDS, hyperemesis gravidarum, anorexia nervosa, hematopoietic stem cell transplantation, Wernicke encephalopathy etc. The market restraints are poor cure rates of central pontine myelinolysis, treatment, high cost of treatment etc.

Central pontine myelinolysis (CPM), also known as osmotic demyelination syndrome or central pontine demyelination, is a neurological disorder caused by severe damage of the myelin sheath of nerve cells.

CPM mostly affects the pons area of the brain and is characterized by acute paralysis, difficulty swallowing (dysphagia), difficulty speaking (dysarthria), and other neurological symptoms. These neurological symptoms are manifested into nausea and vomiting, disturbed consciousness, gait changes, confusion, headache, seizures etc. Serious progressive neurological symptoms are, progressive development of spastic tetraparesis, pseudobulbar palsy etc.

The diagnosis segment of central pontine myelinolysis especially the Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) is growing fast. MRI is the test of choice with its high specificity and correct diagnosis capabilities.

The global CPM market size is expected to reach US$ 2.2 billion by 2023, and the market is projected to grow at a CAGR of ~ 5.5 % during the forecast period 2017-2023.

Global Central pontine myelinolysis Fujifilm Holdings Corporation, GE Healthcare, Siemens Healthcare GmbH, Philips Healthcare (Koninklijke Philips N.V.), Shimadzu Corporation, Toshiba Medical Systems Corporation, Carestream Health, Hitachi Medical Corporation and others.

Regional Analysis

Europe is the second largest market in the world due to high income and healthcare penetration. Europe is led by nations such as Germany and France. UK is expected to be the fastest growing market.

The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new drugs in the US drives the central pontine myelinolysis market. Also, concentration of major research companies in the developed countries of this region is adding fuel to the market growth. The large expenditure on the US healthcare accounting to 16% of GDP also cruises the sale of central pontine myelinolysis treatment.

Article source: https://article-realm.com/article/Sports-Recreation/13424-Central-Pontine-Myelinolysis-Market-to-Experience-Exponential-Growth-by-2023.html